BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 32430854)

  • 1. Clinical Trials with Cytokine-Induced Killer Cells and CAR-T Cell Transplantation for Non-small Cell Lung Cancer Treatment.
    Hung LVM; Ngo HT; Van Pham P
    Adv Exp Med Biol; 2020; 1292():113-130. PubMed ID: 32430854
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chimeric antigen receptor (CAR)-T-cell therapy in non-small-cell lung cancer (NSCLC): current status and future perspectives.
    Qu J; Mei Q; Chen L; Zhou J
    Cancer Immunol Immunother; 2021 Mar; 70(3):619-631. PubMed ID: 33025047
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination of DC/CIK adoptive T cell immunotherapy with chemotherapy in advanced non-small-cell lung cancer (NSCLC) patients: a prospective patients' preference-based study (PPPS).
    Zhao Y; Qiao G; Wang X; Song Y; Zhou X; Jiang N; Zhou L; Huang H; Zhao J; Morse MA; Hobeika A; Ren J; Lyerly HK
    Clin Transl Oncol; 2019 Jun; 21(6):721-728. PubMed ID: 30374838
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness and safety of chemotherapy with cytokine-induced killer cells in non-small cell lung cancer: A systematic review and meta-analysis of 32 randomized controlled trials.
    Xiao Z; Wang CQ; Feng JH; Zhou MH; Wang YZ; Li NN; Sun YP; Liu SY; Yao XS; Li CW; Ma B; Ding J; Chen L
    Cytotherapy; 2019 Feb; 21(2):125-147. PubMed ID: 30554868
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemokine Receptor CCR2b Enhanced Anti-tumor Function of Chimeric Antigen Receptor T Cells Targeting Mesothelin in a Non-small-cell Lung Carcinoma Model.
    Wang Y; Wang J; Yang X; Yang J; Lu P; Zhao L; Li B; Pan H; Jiang Z; Shen X; Liang Z; Liang Y; Zhu H
    Front Immunol; 2021; 12():628906. PubMed ID: 33777013
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting B7-H3 via chimeric antigen receptor T cells and bispecific killer cell engagers augments antitumor response of cytotoxic lymphocytes.
    Liu J; Yang S; Cao B; Zhou G; Zhang F; Wang Y; Wang R; Zhu L; Meng Y; Hu C; Liang H; Lin X; Zhu K; Chen G; Luo KQ; Di L; Zhao Q
    J Hematol Oncol; 2021 Jan; 14(1):21. PubMed ID: 33514401
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adoptive immunotherapy of cytokine-induced killer cell therapy in the treatment of non-small cell lung cancer.
    Wang M; Cao JX; Pan JH; Liu YS; Xu BL; Li D; Zhang XY; Li JL; Liu JL; Wang HB; Wang ZX
    PLoS One; 2014; 9(11):e112662. PubMed ID: 25412106
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Profiling the dynamic expression of checkpoint molecules on cytokine-induced killer cells from non-small-cell lung cancer patients.
    Zhang L; Wang J; Wei F; Wang K; Sun Q; Yang F; Jin H; Zheng Y; Zhao H; Wang L; Yu W; Zhang X; An Y; Yang L; Zhang X; Ren X
    Oncotarget; 2016 Jul; 7(28):43604-43615. PubMed ID: 27283895
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combining antiangiogenic therapy with adoptive cell immunotherapy exerts better antitumor effects in non-small cell lung cancer models.
    Shi S; Wang R; Chen Y; Song H; Chen L; Huang G
    PLoS One; 2013; 8(6):e65757. PubMed ID: 23799045
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chimeric antigen receptor T cell targeting EGFRvIII for metastatic lung cancer therapy.
    Zhang Z; Jiang J; Wu X; Zhang M; Luo D; Zhang R; Li S; He Y; Bian H; Chen Z
    Front Med; 2019 Feb; 13(1):57-68. PubMed ID: 30721445
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dendritic cell immunotherapy combined with cytokine-induced killer cells promotes skewing toward Th2 cytokine profile in patients with metastatic non-small cell lung cancer.
    Zhao P; Bu X; Wei X; Sun W; Xie X; Li C; Guo Q; Zhu D; Wei X; Gao D
    Int Immunopharmacol; 2015 Apr; 25(2):450-6. PubMed ID: 25698555
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased cycles of DC/CIK immunotherapy decreases frequency of Tregs in patients with resected NSCLC.
    Song H; Liu S; Zhao Z; Sun W; Wei X; Ma X; Zhao P; Gao D
    Int Immunopharmacol; 2017 Nov; 52():197-202. PubMed ID: 28941416
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical efficacy and safety of CIK plus radiotherapy for lung cancer: A meta-analysis of 16 randomized controlled trials.
    Xiao Z; Wang CQ; Zhou MH; Li NN; Liu SY; He YJ; Wang YZ; Feng JH; Yao XS; Chen L; Ma B; Yu S; Zeng XT; Li CW; Ding J
    Int Immunopharmacol; 2018 Aug; 61():363-375. PubMed ID: 29945024
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of the number and interval of treatment cycles on cytokine-induced killer cells and their adjuvant therapeutic effects in advanced non-small-cell lung cancer (NSCLC).
    Gu Y; Lv H; Zhao J; Li Q; Mu G; Li J; Wuyang J; Lou G; Wang R; Zhang Y; Huang X
    Int Immunopharmacol; 2017 Sep; 50():263-269. PubMed ID: 28711032
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chimeric antigen receptor-modified T Cells inhibit the growth and metastases of established tissue factor-positive tumors in NOG mice.
    Zhang Q; Wang H; Li H; Xu J; Tian K; Yang J; Lu Z; Zheng J
    Oncotarget; 2017 Feb; 8(6):9488-9499. PubMed ID: 28055955
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evolving insights into the improvement of adoptive T-cell immunotherapy through PD-1/PD-L1 blockade in the clinical spectrum of lung cancer.
    Li Y; Sharma A; Schmidt-Wolf IGH
    Mol Cancer; 2024 Apr; 23(1):80. PubMed ID: 38659003
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antitumor activity of EGFR-specific CAR T cells against non-small-cell lung cancer cells in vitro and in mice.
    Li H; Huang Y; Jiang DQ; Cui LZ; He Z; Wang C; Zhang ZW; Zhu HL; Ding YM; Li LF; Li Q; Jin HJ; Qian QJ
    Cell Death Dis; 2018 Feb; 9(2):177. PubMed ID: 29415996
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Antitumor Immunity and Tumor Responses of Chemotherapy with or without DC-CIK for Non-Small-Cell Lung Cancer in China: A Meta-Analysis of 28 Randomized Controlled Trials.
    Xiao Z; Wang CQ; Zhou MH; Li NN; Sun YP; Wang YZ; Liu SY; Yu HS; Li CW; Zeng XT; Chen L; Yao XS; Feng JH
    J Immunol Res; 2018; 2018():9081938. PubMed ID: 30648123
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prospective study of chemotherapy in combination with cytokine-induced killer cells in patients suffering from advanced non-small cell lung cancer.
    Wu C; Jiang J; Shi L; Xu N
    Anticancer Res; 2008; 28(6B):3997-4002. PubMed ID: 19192663
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of dendritic cells co-cultured with cytokine-induced killer cells immunotherapy for non-small-cell lung cancer.
    Wang S; Wang Z
    Int Immunopharmacol; 2015 Sep; 28(1):22-8. PubMed ID: 26013109
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.